Evidence map›Paper›PMID 23228169›Full record

ArticleBMC cancer2012

GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers.

Sylvia Hartmann, Claudio Agostinelli, Jürgen Diener, Claudia Döring, Stefano Fanti, Pier Luigi Zinzani, Andrea Gallamini, Lothar Bergmann, Stefano Pileri, Martin-Leo Hansmann

Abstract read
In one paragraph

Article in BMC cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Vasculature cast sign onEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. The PI3K pathway in B cell metabolism.Critical reviews in biochemistry and molecular biology · 2016
    Review
  14. Article
  15. FDG PET/CT imaging as a biomarker in lymphoma.European journal of nuclear medicine and molecular imaging · 2015
    Review
  16. Baseline metabolic tumour volume in Hodgkin lymphoma: the prognostic value of accessory cells.European journal of nuclear medicine and molecular imaging · 2014
    Article
  17. Role of PET in lymphoma.Current treatment options in oncology · 2014
    Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sylvia HartmannSenckenberg Institute of Pathology, Goethe University, Frankfurt am Main, Germany. s.hartmann@em.uni-frankfurt.de
Claudio Agostinelli
Jürgen Diener
Claudia Döring
Stefano Fanti
Pier Luigi Zinzani
Andrea Gallamini
Lothar Bergmann
Stefano Pileri
Martin-Leo Hansmann

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIncreased glycolytic activity is a hallmark of cancer, allowing staging and restaging with 18F-fluorodeoxyglucose-positron-emission-tomography (PET). Since interim-PET is an important prognostic tool in Hodgkin lymphoma (HL), the aim of this study was to investigate the expression of proteins involved in the regulation of glucose metabolism in the different HL subtypes and their impact on clinical outcome.

methodsLymph node biopsies from 54 HL cases and reactive lymphoid tissue were stained for glucose transporter 1 (GLUT1), lactate dehydrogenase A (LDHA) and lactate exporter proteins MCT1 and MCT4. In a second series, samples from additional 153 HL cases with available clinical data were stained for GLUT1 and LDHA.

resultsMembrane bound GLUT1 expression was frequently observed in the tumor cells of HL (49% of all cases) but showed a broad variety between the different Hodgkin lymphoma subtypes: Nodular sclerosing HL subtype displayed a membrane bound GLUT1 expression in the Hodgkin-and Reed-Sternberg cells in 56% of the cases. However, membrane bound GLUT1 expression was more rarely observed in tumor cells of lymphocyte rich classical HL subtype (30%) or nodular lymphocyte predominant HL subtype (15%). Interestingly, in both of these lymphocyte rich HL subtypes as well as in progressively transformed germinal centers, reactive B cells displayed strong expression of GLUT1. LDHA, acting downstream of glycolysis, was also expressed in 44% of all cases. We evaluated the prognostic value of different GLUT1 and LDHA expression patterns; however, no significant differences in progression free or overall survival were found between patients exhibiting different GLUT1 or LDHA expression patterns. There was no correlation between GLUT1 expression in HRS cells and PET standard uptake values.

conclusionsIn a large number of cases, HRS cells in classical HL express high levels of GLUT1 and LDHA indicating glycolytic activity in the tumor cells. Although interim-PET is an important prognostic tool, a predictive value of GLUT1 or LDHA staining of the primary diagnostic biopsy could not be demonstrated. However, we observed GLUT1 expression in progressively transformed germinal centers and hyperplastic follicles, explaining false positive results in PET. Therefore, PET findings suggestive of HL relapse should always be confirmed by histology.

Indexed as

AdultBiomarkers, TumorDisease-Free SurvivalFemaleGerminal CenterGlucose Transporter Type 1Hodgkin DiseaseHumansKaplan-Meier EstimateMalePositron-Emission TomographyPrognosisBiomarkers, TumorGlucose Transporter Type 1

Identifiers

PMID23228169
PMCPMC3537691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.